SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Meta Expands AI Training With Employee Activity Tracking Tools 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
BERKELEY, Calif., May 15, 2017 -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, announced today that Jim Neal, Chief Executive Officer, will present the Company’s new strategic initiatives and value drivers at the UBS Global Healthcare Conference on Monday, May 22, 2017, at 8:30 a.m. ET. The conference is being held at the Grand Hyatt New York hotel.
A live audio webcast of the presentation can be accessed in the Investors and Media section of XOMA's website at http://investors.xoma.com/events.cfm. An archived version of the webcast will be available via replay for 90 days following the presentation.
About XOMA Corporation
XOMA has an extensive portfolio of products, programs, and technologies that are the subject of licenses the Company has in place with other biotech and pharmaceutical companies. Many of these licenses are the result of the Company’s pioneering efforts in the discovery and development of antibody therapeutics. There are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. In order to maximize its value in a licensing transaction, XOMA continues to invest in X358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. For more information, visit www.xoma.com.
CONTACTS: Investor contact: Luke Heagle Pure Communications +1 910-726-1372 [email protected] Media contact: Colin Sanford Pure Communications +1 415-946-1094 [email protected]
